2.7.5　参考文献

Baumann A, Tuerck D, Prabhu S, Dickmann L, Sims J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov Today. 2014;19(10):1623 31. doi: 10.1016/j.drudis.2014.06.002

Carone FA, Peterson DR, Oparil S, Pullman TN. Renal tubular transport and catabolism of proteins and peptides. Kidney Int. 1979;16(3):271-8. doi: 10.1038/ki.1979.129.

Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547-561. doi: 10.1016/S0885-3924(02)00529-8.

Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 data in randomised controlled trials. Eur J Cancer. 2008;44(13): 1793-8. doi: 10.1016/j.ejca.2008.05.008

DeZern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol. 2013;90(1):16–24. doi: 10.1111/ejh.12021

Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E, Garcia-Manero G. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Cancer Medicine. 2019;8:543-553.

Highlights of prescribing information for Soliris (eculizumab) injection, for intravenous use. Drugs@FDA. Revised November 2020.

Highlights of prescribing information for Ultomiris (ravulizumab-cwvz) injection, for intravenous use. Revised January 2022.

Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. doi: 10.1038/nrdp.2017.28

Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253-1258. doi: 10.1056/NEJM199511093331904

Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-1243. doi: 10.1056/NEJMoa061648

Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037. doi: 10.1056/NEJMoa2029073. PMID: 33730455.

Hydery T, Coppenrath VA. A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria. Drug Target Insights. 2019;13:1-8. doi: 10.1177/1177392819857089.

Ivens IA, Achanzar W, Baumann A, et al. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development. Toxicol Pathol. 2015;43(7):959-983.

Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5 inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540-549. doi: 10.1182/blood-2018-09-876805

Lee JW, de Fontbrune FS, Lee LWL, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530-539. doi: 10.1182/blood-2018-09-876136

Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014;5(1):98-126. doi: 10.4161/viru.26515.

Mallinckrodt CH, Lane, PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J. 2008;42(4):303-319. doi: 10.1177/009286150804200402

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD. Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria. Semin Hematol. 2018;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002

McKinley C, Richards S, Munir T, et al. Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome. Blood. 2017;130(suppl 1):3471. doi: 10.1182/blood.V130.Suppl_1.3471.3471

McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734-737. doi: 10.15585/mmwr.mm6627e1

Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699-3709. doi: 10.1182/blood-2005-04-1717

Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97(11):1666-1673. doi: 10.3324/haematol.2012.062828

Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol. 2015;67(1):56-70. doi: 10.1016/j.molimm.2015.02.030

Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094-4100. doi: 10.1182/blood-2008-11-189944

Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi: 10.3389/fimmu.2019.01157

Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922-929. doi: 10.3324/haematol.2013.093161

Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505-1514. doi: 10.1007/s00277-020-04052-z

Socié G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297-310. doi: 10.1111/bjh.15790

Soliris. Summary of Product Characteristics (SmPC). 2021

Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:2040620719874728. doi: 10.1177/2040620719874728

Tibbitts J, Canter D, Graff R, Smith A, Khawli LA. Key Factors Influencing ADME Properties of Therapeutic Proteins: A Need for ADME Characterization in Drug Discovery and Development. MAbs. 2016;8(2):229-245. doi: 10.1080/19420862.2015.1115937

Turecek PL, Siekmann J. PEG-protein conjugates: nonclinical and clinical toxicity considerations. Polymer-Protein Conjugates. 2020: 61-101. doi: 10.1016/B978-0-444-64081-9.00004-8.

Ultomiris. Summary of Product Characteristics (SmPC). 2021

US Food and Drug Administration. Briefing information for the November 18, 2014 meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM). Updated November 14, 2014. Accessed June 30, 2020.

Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344(14):1058-1066. doi: 10.1056/NEJM200104053441406

Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344(15):1140-1144. doi: 10.1056/NEJM200104123441506

Xue L, Clements-Egan A, Amaravadi L, et al. Recommendations for the assessment and management of pre-existing drug-reactive antibodies during biotherapeutic development. AAPS J. 2017;19(6):1576-1586. doi: 10.1208/s12248-017-0153-x

Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(5):655-677. doi: 10.1002/wnan.1339

ユルトミリス点滴静注 300mg、ユルトミリス HI 点滴静注 300mg/3mL、ユルトミリス HI 点滴静注 1100mg/11mL 添付文書、2022 年 1 月改訂（第 5 版）

大野良之：特定疾患治療研究事業未対象疾患の疫学像を把握するための調査研究班、平成 11 年度研究業績集―最終報告書―2000 年 3 月発行、https://mhlw-grants.niph.go.jp/project/3542

国立感染症研究所厚生労働省健康局結核感染症課、侵襲性髄膜炎菌感染症 2013 年 4 月～2017 年 10 月、In:病原微生物検出情報、2018 年 1 月発行、Vol.39 No.1 (No. 455), p.1-9.

難病情報センター、2015～2019 年度の特定医療費受給者証所持者数、https://www.nanbyou.or.jp/entry/5354

発作性夜間ヘモグロビン尿症診療の参照ガイド 令和 1 年改訂版:特発性造血障害に関する調査研究班、改訂版作成のためのワーキンググループ、2020 年 3 月発行